Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06199713 · ClinicalTrials.gov registry record
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
A clinical trial of Melanoma and Unresectable Melanoma, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT06199713 is a study of Melanoma and Unresectable Melanoma that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 24 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06199713, a study of Melanoma and Unresectable Melanoma, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Study Locations (1)
Wisconsin
- University of Wisconsin Hospitals and Clinics (UWHC) - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2029-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06199713
The ClinicalTrials.gov registry entry for NCT06199713 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (97% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography is the first listed.
NCT06199713 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06199713 about?
NCT06199713 is a clinical study titled "Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients". The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side...
What is the current status of trial NCT06199713?
This trial is currently recruiting. The enrollment target is 24 participants. The study started on 2024-01-30. Estimated completion is 2029-01.
What conditions does trial NCT06199713 study?
This clinical trial studies the following conditions: Melanoma, Unresectable Melanoma, Melanoma Stage IV, Melanoma Stage III.
What interventions are being tested in trial NCT06199713?
The interventions under investigation include: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06199713?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06199713 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.